STOCK TITAN
  1. Home
  2. News
  3. XENE

Xenon Pharmaceuticals Inc - XENE STOCK NEWS

Welcome to our dedicated news page for Xenon Pharmaceuticals (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Xenon Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Xenon Pharmaceuticals's position in the market.

News
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (XENE) to provide updates on neurology programs at AES 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced the pricing of its upsized underwritten public offering of 8,461,542 common shares and pre-funded warrants, with expected gross proceeds of approximately $300.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.39%
Tags
offering
-
News
Xenon Pharmaceuticals Announces Proposed Public Offering
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has announced the commencement of an underwritten public offering of $225.0 million of its common shares and pre-funded warrants to purchase common shares. The proposed offering is subject to market conditions and will be made by means of a written prospectus and prospectus supplement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.39%
Tags
offering
News
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (XENE) reported topline results from the X-NOVA clinical trial evaluating XEN1101 for major depressive disorder, showing clinically meaningful drug activity and early onset of efficacy, with a favorable tolerability and safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.78%
Tags
clinical trial
-
News
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announces that the Phase 2 clinical trial for NBI-921352 in adult patients with focal onset seizures (FOS) failed to show a meaningful reduction in seizure frequency. No further development with NBI-921352 in FOS is planned at this time. Xenon will review the data to understand potential implications for the second ongoing study with NBI-921352 in SCN8A-developmental epileptic encephalopathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
none
-
News
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) reported financial results for Q3 2023 and provided an update on the XEN1101 Phase 2 X-NOVA clinical trial for major depressive disorder. XEN1101 Phase 3 epilepsy program continues to progress, with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures. Patient enrollment in X-TOLE2 expected to complete in the second half of 2024. The company's cash and cash equivalents were $639.1 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.69%
Tags
earnings
News
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
Rhea-AI Summary
Xenon Pharmaceuticals Inc. will report its Q3 2023 financial and operating results on November 8, 2023, after the close of U.S. financial markets. A conference call and webcast will be held at 4:30 pm Eastern Time. Dial-in and webcast details are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.93%
Tags
earnings
-
News
Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
Rhea-AI Summary
Xenon Pharmaceuticals announces publication of Phase 2b trial results for XEN1101 in JAMA Neurology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
clinical trial
-
News
Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
Rhea-AI Summary
Xenon Pharmaceuticals to present at Jefferies Inaugural Biotech CNS/Neuro Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
conferences
News
Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
Rhea-AI Summary
Xenon Pharmaceuticals to present at TD Cowen's summit on September 20, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
conferences
Stock XENE logo
Xenon Pharmaceuticals Inc

Nasdaq:XENE

XENE Rankings

#1526 Ranked by Market Cap
#3064 Ranked by Stock Gains
N/A Ranked by Dividends

XENE Stock Data

3.12B
69.56M
0.38%
99.99%
3.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Burnaby

About XENE

xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.